NF2-SWN Meetup: Progress Update on the INTUITT-NF2 Clinical Trial

Recorded live on May 3, 2023, this NF2-SWN Accelerator Meetup discussed an exciting progress update on the NF2-INTUITT clinical trial, a first-of-its-kind platform trial dedicated to treatment for NF2-related schwannomatosis (NF2-SWN). The first drug entered into the NF2-INTUITT trial was Brigatinib, which showed promise as a result of CTF’s groundbreaking Synodos for NF2 research collaboration. CTF has proudly continued this investment as a co-funder of this trial. This webinar shares the latest on this promising progress, and CTF’s commitment bringing more drugs into the platform trial. To enable Closed Captions, click the CC button. To read the transcription of this video, click this link: https://docs.google.com/document/d/1q... About NF: NF refers to genetic conditions that cause tumors to grow on nerves throughout the body. NF includes all forms of neurofibromatosis and schwannomatosis and affects about 4 million people worldwide. Anyone can be born with NF, and it affects everyone differently. There is no cure yet. About the Children's Tumor Foundation: Children’s Tumor Foundation (CTF) began as the first grassroots organization solely dedicated to finding treatments for NF. Today, CTF is a highly recognized global nonprofit foundation, the leading force in the fight to end NF, and a model for other innovative research endeavors. Visit our website at https://www.ctf.org/ Donate today at https://www.ctf.org/ways-to-give/ Follow us on our social media platforms: Facebook -   / childrenstumor   Instagram -   / childrenstumor   Twitter -   / childrenstumor   LinkedIn -   / children's-tumor-foundation   #endnf #nf1 #nf2 #nf2swn #swn #childrenstumor #neurofibromatosis #schwannomatosis #nervetumor #tumor